Observational Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jun 14, 2016; 22(22): 5267-5275
Published online Jun 14, 2016. doi: 10.3748/wjg.v22.i22.5267
Table 1 Demographic and disease characteristics n (%)
UC (n = 508)CD (n = 196)
Smoking habit
Active47 (9)31 (16)
Discontinued75 (15)34 (17)
Family history of IBD59 (12)19 (10)
Extraintestinal manifestations
Articular156 (31)87 (44)
Dermatological11 (2)10 (5)
Ocular8 (2)3 (2)
Other31 (6)15 (8)
Table 2 Extent, location and behavior of inflammatory bowel disease according to the montreal classification n (%)
UC (n = 508)CD (n = 196)
UC Extent
E1: Ulcerative proctitis142 (28)
E2: Left sided UC112 (22)
E3: Extensive UC (pancolitis)254 (50)
CD Location
L1: Ileal53 (27)
L2: Colonic87 (44)
L3: Ileocolonic55 (28)
L4: Upper gastrointestinal5 (3)
CD Behavior
B1: Non-stricturing/non-penetrating157 (80)
B2: Stricturing20 (10)
B3: Penetrating18 (9)
p: Perianal disease55 (28)
Table 3 Medical treatment, hospitalizations and surgery in patients with inflammatory bowel disease n (%)
UC (n = 508)CD (n = 196)P value
Corticosteroids297 (58)133 (68)< 0.05
Mesalazine (oral, local or both)497 (98)133 (68)< 0.01
Immunosupressive agents166 (33)132 (67)< 0.01
Ciclosporine7 (1)2 (1)
Biologic therapy34 (7)67 (34)< 0.01
Surgery27 (5)75 (38)< 0.01
Intestinal resection27 (5)50 (25)< 0.01
Hospitalizations176 (35)108 (55)< 0.01
1113 (64)50 (46.3)< 0.01
2-345 (26)35 (32.3)
≥ 418 (10)23 (21.3)< 0.011